Ricks takes baton from Caforio at PhRMA; plus Bluestone joins Gilead board and Derrick Li returns to investment banking, joining Baird

David Ricks has become chairman of PhRMA. The chairman and CEO of Eli Lilly and Co. (NYSE:LLY) succeeds Giovanni Caforio, chairman and CEO of Bristol Myers Squibb Co. (NYSE:BMY). PhRMA also announced that the CSL Behring unit of CSL Ltd. (ASX:CSL) has joined the trade group. 

Jeffrey Bluestone was appointed to the board of directors at  Gilead Sciences Inc. (NASDAQ:GILD). Bluestone is the president and CEO of Sonoma Biotherapeutics and the A.W. and Mary Margaret Clausen Distinguished Professor of metabolism and endocrinology at the University of California San Francisco...